| Name | Title | Contact Details |
|---|
Shasta Regional Medical Center is a 226-bed acute care, medical and surgical facility with a full range of ancillary services. We have been serving far Northern California since 1945. Our hospital has a highly efficient and expanded Emergency Department with minimal patient wait times, a technologically advanced cardiac cath lab available 24/7, an accredited Stroke Team and digital (filmless) radiology services. We have more than 600 registered nurses, technicians, and support personnel working alongside more than 300 physicians on staff. Together, our staff is committed to combining the latest proven technology with personal care and attention to help our patients get better.
Global Clinical Trials is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Talecris Plasma is a Corpus Christi, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.